{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:16:53Z","timestamp":1792081013980,"version":"4.4.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03429-z","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:42:23Z","timestamp":1776811343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrative Perspectives on Pirfenidone: Mechanistic Insights, Pharmacodynamics, and Emerging Therapeutic Strategies for Fibrotic Disorders"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5902-7407","authenticated-orcid":false,"given":"Abhidnya","family":"Kudterkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-1741","authenticated-orcid":false,"given":"Sarika","family":"Wairkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"3429_CR1","doi-asserted-by":"publisher","unstructured":"Zhang L, Zhang J, Guo Y, Yan J. The disease burden of ILD at the global, regional, and national levels from 1990 to 2021, and projections until 2035: the 2021 Global Burden of Disease study. Front. Med. (Lausanne). Frontiers Media SA; 2025.  https:\/\/doi.org\/10.3389\/fmed.2025.1637654","DOI":"10.3389\/fmed.2025.1637654"},{"key":"3429_CR2","doi-asserted-by":"publisher","unstructured":"Bramhill CI, Langan D, Mulryan H, Eustace-Cook JI, RussellID A-M, BradyID A-M. A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF) Methods. 2024;  https:\/\/doi.org\/10.1371\/journal.pone.0297832","DOI":"10.1371\/journal.pone.0297832"},{"key":"3429_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-025-03916-2","author":"F Lalla","year":"2025","unstructured":"Lalla F, Latella A, Varone F, Iovene B, Richeldi L, Sgalla G, et al. Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study. BMC Pulm Med. 2025. https:\/\/doi.org\/10.1186\/s12890-025-03916-2.","journal-title":"BMC Pulm Med"},{"key":"3429_CR4","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903501539","author":"ME Cho","year":"2010","unstructured":"Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs. 2010. https:\/\/doi.org\/10.1517\/13543780903501539.","journal-title":"Expert Opin Investig Drugs"},{"key":"3429_CR5","doi-asserted-by":"publisher","first-page":"26704","DOI":"10.1021\/acsnano.4c06598","volume":"18","author":"Y Xie","year":"2024","unstructured":"Xie Y, Shi S, Lv W, Wang X, Yue L, Deng C, et al. Tetrahedral framework nucleic acids delivery of pirfenidone for anti-inflammatory and antioxidative effects to treat idiopathic pulmonary fibrosis. ACS Nano. 2024;18:26704\u201321. https:\/\/doi.org\/10.1021\/acsnano.4c06598.","journal-title":"ACS Nano"},{"key":"3429_CR6","doi-asserted-by":"publisher","unstructured":"Yao M, Sun M, Chen C, Jin L, Yang H, Li Y, et al. Novel pirfenidone derivatives: synthesis and biological evaluation. RSC Med Chem. Royal Society of Chemistry. 2023;14:1158\u201364. https:\/\/doi.org\/10.1039\/d3md00072a","DOI":"10.1039\/d3md00072a"},{"issue":"1","key":"3429_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/01902149809046058","volume":"24","author":"SN Iyer","year":"1998","unstructured":"Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res. 1998;24(1):119\u201332. https:\/\/doi.org\/10.3109\/01902149809046058.","journal-title":"Exp Lung Res"},{"key":"3429_CR8","unstructured":"U.S. Food and Drug Administration. Orphan drug designations and approvals: Pirfenidone (ESBRIET) [Internet]. Silver Spring (MD): FDA; 2025. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=177903. Accessed 22 June 2025."},{"key":"3429_CR9","doi-asserted-by":"publisher","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. BioMed Central Ltd; 2021;21. https:\/\/doi.org\/10.1186\/s12890-021-01783-1","DOI":"10.1186\/s12890-021-01783-1"},{"key":"3429_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","volume":"171","author":"A Azuma","year":"2005","unstructured":"Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040\u20137. https:\/\/doi.org\/10.1164\/rccm.200404-571OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"3429_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S37233","author":"Y Takeda","year":"2014","unstructured":"Takeda Y, Tsujino K, Kijima T, Kumanogoh A, DOVE Medical Press Ltd. Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis. Patient Prefer Adherence. 2014. https:\/\/doi.org\/10.2147\/PPA.S37233.","journal-title":"Patient Prefer Adherence"},{"key":"3429_CR12","doi-asserted-by":"publisher","unstructured":"Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res. BioMed Central Ltd.; 2011;12. https:\/\/doi.org\/10.1186\/1465-9921-12-143","DOI":"10.1186\/1465-9921-12-143"},{"key":"3429_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821\u20139. https:\/\/doi.org\/10.1183\/09031936.00005209.","journal-title":"Eur Respir J"},{"key":"3429_CR14","doi-asserted-by":"publisher","DOI":"10.3402\/ecrj.v3.32608","volume":"3","author":"GN Salih","year":"2016","unstructured":"Salih GN, Shaker SB, Madsen HD, Bendstrup E, Informa UK Limited. Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J. 2016;3:32608. https:\/\/doi.org\/10.3402\/ecrj.v3.32608.","journal-title":"Eur Clin Respir J"},{"key":"3429_CR15","doi-asserted-by":"publisher","unstructured":"Mortensen A, Cherrier L, Walia R. Effect of pirfenidone on wound healing in lung transplant patients. Multidiscip Respir Med. BioMed Central Ltd.; 2018;13. https:\/\/doi.org\/10.1186\/s40248-018-0129-4","DOI":"10.1186\/s40248-018-0129-4"},{"key":"3429_CR16","doi-asserted-by":"publisher","unstructured":"Khanna D, Albera C, Fischer A, Khalidi N, Raghu G, Chung L, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial. J Rheumatol. Journal of Rheumatology; 2016;43:1672\u20139. https:\/\/doi.org\/10.3899\/jrheum.151322","DOI":"10.3899\/jrheum.151322"},{"key":"3429_CR17","doi-asserted-by":"publisher","unstructured":"Gasca-Lozano LE, Lucano-Landeros S, Ruiz-Mercado H, Salazar-Montes A, Sandoval-Rodr\u00edguez A, Garcia-Ba\u00f1uelos J, et al. Pirfenidone Accelerates Wound Healing in Chronic Diabetic Foot Ulcers: A Randomized, Double-Blind Controlled Trial. J Diabetes Res. Hindawi Limited; 2017;2017. https:\/\/doi.org\/10.1155\/2017\/3159798","DOI":"10.1155\/2017\/3159798"},{"key":"3429_CR18","doi-asserted-by":"publisher","unstructured":"Lancaster L, Albera C, Bradford WZ, Costabel U, Du Bois RM, Fagan EA, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: Integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. BMJ Publishing Group; 2016;3. https:\/\/doi.org\/10.1136\/bmjresp-2015-000105","DOI":"10.1136\/bmjresp-2015-000105"},{"key":"3429_CR19","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.21037\/jtd-23-946","volume":"15","author":"J Lee","year":"2023","unstructured":"Lee J, Song JU, AME Publishing Company. Safety and tolerability of combination treatment with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. J Thorac Dis. 2023;15:5913\u201321. https:\/\/doi.org\/10.21037\/jtd-23-946.","journal-title":"J Thorac Dis"},{"key":"3429_CR20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140","volume":"377","author":"B Md","year":"2011","unstructured":"Md B, Kardatzke D, Noble PW, Albera C, Bradford WZ, Costabel U, et al. Articles Pirfenidone in patients with idiopathic pulmonary fi brosis (CAPACITY): two randomised trials. The Lancet [Internet]. 2011;377:1760\u20139. https:\/\/doi.org\/10.1016\/S0140.","journal-title":"The Lancet [Internet]"},{"key":"3429_CR21","unstructured":"Therapeutic Goods Administration. Australian public assessment report for pirfenidone (Esbriet) [Internet]. Canberra (ACT): TGA; 2016. Available from:\u00a0https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-pirfenidone-160809.pdf. Accessed 26 June 2025."},{"key":"3429_CR22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1107\/S2056989019006418","volume":"75","author":"M Barbero","year":"2019","unstructured":"Barbero M, Mossotti M, Sironi A, Giovenzana GB, Colombo V, International Union of Crystallography. Crystal structure of pirfenidone (5-methyl-1-phenyl-1H-pyridin-2-one): an active pharmaceutical ingredient (API). Acta Crystallogr Sect E Crystallogr Commun. 2019;75:984\u20136. https:\/\/doi.org\/10.1107\/S2056989019006418.","journal-title":"Acta Crystallogr Sect E Crystallogr Commun"},{"key":"3429_CR23","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00001111","author":"CJ Schaefer","year":"2011","unstructured":"Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011. https:\/\/doi.org\/10.1183\/09059180.00001111.","journal-title":"Eur Respir Rev"},{"key":"3429_CR24","doi-asserted-by":"crossref","unstructured":"Mac\u00edas-Barrag\u00e1n J, Sandoval-Rodr\u00edguez A, Navarro-Partida J, Armend\u00e1riz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair [Internet]. 2010;3(1):16. Available from:\u00a0http:\/\/www.fibrogenesis.com\/content\/3\/1\/16. Accessed 19 June 2025.","DOI":"10.1186\/1755-1536-3-16"},{"key":"3429_CR25","unstructured":"U.S. Food and Drug Administration. ESBRIET (pirfenidone) prescribing information [Internet]. Silver Spring (MD): FDA; 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022535s000lbl.pdf. Accessed 30 June 2025."},{"key":"3429_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0350-9","author":"ES Kim","year":"2015","unstructured":"Kim ES, Keating GM, Springer International Publishing. Pirfenidone: a review of its use in idiopathic pulmonary fibrosis. Drugs. 2015. https:\/\/doi.org\/10.1007\/s40265-015-0350-9.","journal-title":"Drugs"},{"key":"3429_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pupt.2009.03.003","volume":"22","author":"CM Rubino","year":"2009","unstructured":"Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22:279\u201385. https:\/\/doi.org\/10.1016\/j.pupt.2009.03.003.","journal-title":"Pulm Pharmacol Ther"},{"key":"3429_CR28","unstructured":"European Medicines Agency. Assessment report for Esbriet (pirfenidone) [Internet]. Amsterdam (NL): EMA; 2011. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/esbriet-epar-public-assessment-report_en.pdf. Accessed 26 June 2025."},{"key":"3429_CR29","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1080\/00498254.2021.2007553","volume":"51","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Sato R, Fukami T, Nakano M, Nakajima M. Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver. Xenobiotica. 2021;51:1352\u20139. https:\/\/doi.org\/10.1080\/00498254.2021.2007553.","journal-title":"Xenobiotica"},{"key":"3429_CR30","doi-asserted-by":"publisher","unstructured":"Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, et al. No relevant pharmacokinetic drug\u2013drug interaction between nintedanib and pirfenidone. European Respiratory Journal. European Respiratory Society; 2019;53. https:\/\/doi.org\/10.1183\/13993003.01060-2018","DOI":"10.1183\/13993003.01060-2018"},{"key":"3429_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-med-120214-013614","volume":"67","author":"AS Selvaggio","year":"2016","unstructured":"Selvaggio AS, Noble PW, Annual Reviews Inc. Pirfenidone initiates a new era in the treatment of idiopathic pulmonary fibrosis. Annu Rev Med. 2016;67:487\u201395. https:\/\/doi.org\/10.1146\/annurev-med-120214-013614.","journal-title":"Annu Rev Med"},{"key":"3429_CR32","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0091270007304104","volume":"47","author":"S Shi","year":"2007","unstructured":"Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007;47:1268\u201376. https:\/\/doi.org\/10.1177\/0091270007304104.","journal-title":"J Clin Pharmacol"},{"key":"3429_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121048","author":"SA Antar","year":"2022","unstructured":"Antar SA, Saleh MA, Al-Karmalawy AA, Elsevier Inc. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and\/or anti-SARS-CoV-2. Life Sci. 2022. https:\/\/doi.org\/10.1016\/j.lfs.2022.121048.","journal-title":"Life Sci"},{"key":"3429_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biom11101424","author":"SB Wu","year":"2021","unstructured":"Wu SB, Hou TY, Kau HC, Tsai CC, MDPI. Effect of pirfenidone on TGF-\u03b21-induced myofibroblast differentiation and extracellular matrix homeostasis of human orbital fibroblasts in graves\u2019 ophthalmopathy. Biomolecules. 2021. https:\/\/doi.org\/10.3390\/biom11101424.","journal-title":"Biomolecules"},{"key":"3429_CR35","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2019-0328TR","author":"SM Ruwanpura","year":"2020","unstructured":"Ruwanpura SM, Thomas BJ, Bardin PG, American Thoracic Society. Pirfenidone: molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol. 2020. https:\/\/doi.org\/10.1165\/rcmb.2019-0328TR.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3429_CR36","doi-asserted-by":"publisher","unstructured":"Bracco Gartner TCL, Crnko S, Leiteris L, van Adrichem I, van Laake LW, Bouten CVC, et al. Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis. Front Cardiovasc Med. Frontiers Media S.A.; 2022;9. https:\/\/doi.org\/10.3389\/fcvm.2022.854314","DOI":"10.3389\/fcvm.2022.854314"},{"key":"3429_CR37","doi-asserted-by":"publisher","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis An Official ATS\/ERS\/JRS\/ALAT Clinical practice guideline. Am J Respir Crit Care Med. American Thoracic Society; 2018;198:e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"3429_CR38","doi-asserted-by":"crossref","unstructured":"Selman M, Pardo A. The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis. Cell Signal. Elsevier Inc.; 2020;66. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109482","DOI":"10.1016\/j.cellsig.2019.109482"},{"key":"3429_CR39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00073012","author":"WA Wuyts","year":"2013","unstructured":"Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J. 2013. https:\/\/doi.org\/10.1183\/09031936.00073012.","journal-title":"Eur Respir J"},{"key":"3429_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1093-z","author":"J Jin","year":"2019","unstructured":"Jin J, Togo S, Kadoya K, Tulafu M, Namba Y, Iwai M, et al. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-\u03b21. Respir Res. 2019. https:\/\/doi.org\/10.1186\/s12931-019-1093-z.","journal-title":"Respir Res"},{"key":"3429_CR41","doi-asserted-by":"publisher","unstructured":"Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-\u03b2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. Elsevier; 2014;58:13\u20139. https:\/\/doi.org\/10.1016\/j.ejps.2014.02.014","DOI":"10.1016\/j.ejps.2014.02.014"},{"key":"3429_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-12-24","author":"K Hisatomi","year":"2012","unstructured":"Hisatomi K, Mukae H, Sakamoto N, Ishimatsu Y, Kakugawa T, Hara S, et al. Pirfenidone inhibits TGF-\u03b21-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med. 2012. https:\/\/doi.org\/10.1186\/1471-2466-12-24.","journal-title":"BMC Pulm Med"},{"key":"3429_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pupt.2018.10.006","volume":"53","author":"Z Ma","year":"2018","unstructured":"Ma Z, Zhao C, Chen Q, Yu C, Zhang H, Zhang Z, et al. Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo. Pulm Pharmacol Ther. 2018;53:100\u20136. https:\/\/doi.org\/10.1016\/j.pupt.2018.10.006.","journal-title":"Pulm Pharmacol Ther"},{"key":"3429_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1183\/09031936.04.00120803","volume":"24","author":"T Kakugawa","year":"2004","unstructured":"Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J. 2004;24:57\u201365. https:\/\/doi.org\/10.1183\/09031936.04.00120803.","journal-title":"Eur Respir J"},{"key":"3429_CR45","unstructured":"Adigun R, Goyal A, Bansal P. Systemic sclerosis (scleroderma) [Internet]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from:\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430875. Accessed 27 June 2025."},{"key":"3429_CR46","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2024.0940","author":"WJ Kerrigan","year":"2025","unstructured":"Kerrigan WJ, Church AC, Herrick AL. Systemic Sclerosis-recent advances in diagnosis and management. Br J Hosp Med. 2025. https:\/\/doi.org\/10.12968\/hmed.2024.0940.","journal-title":"Br J Hosp Med"},{"key":"3429_CR47","doi-asserted-by":"crossref","unstructured":"Gy\u00f6rfi AH, Matei AE, Distler JHW. Targeting TGF-\u03b2 signaling for the treatment of fibrosis. Matrix Biology. Elsevier B.V.; 2018. p. 8\u201327. https:\/\/doi.org\/10.1016\/j.matbio.2017.12.016","DOI":"10.1016\/j.matbio.2017.12.016"},{"key":"3429_CR48","doi-asserted-by":"publisher","unstructured":"Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, et al. American Thoracic Society Documents Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations An Official American Thoracic Society Clinical Practice Guideline. 2024; https:\/\/doi.org\/10.1513\/AnnalsATS","DOI":"10.1513\/AnnalsATS"},{"key":"3429_CR49","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","volume":"40","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sharma SK, Mishra D, Dhooria S, Dhir V, Jain S. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease\u2014a randomised controlled trial. Rheumatol Int. 2020;40:703\u201310. https:\/\/doi.org\/10.1007\/s00296-020-04565-w.","journal-title":"Rheumatol Int"},{"key":"3429_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/0970-2113.148451","volume":"32","author":"ZF Udwadia","year":"2015","unstructured":"Udwadia ZF, Mullerpattan JB, Balakrishnan C, Richeldi L. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India. 2015;32:50\u20132. https:\/\/doi.org\/10.4103\/0970-2113.148451.","journal-title":"Lung India"},{"key":"3429_CR51","doi-asserted-by":"publisher","unstructured":"Shah P V, Balani P, Lopez AR, Nobleza CMN, Siddiqui M, Khan S. A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases. Cureus. Springer Science and Business Media LLC; 2021; https:\/\/doi.org\/10.7759\/cureus.12482","DOI":"10.7759\/cureus.12482"},{"key":"3429_CR52","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.1.4503","author":"B-S Lee","year":"1998","unstructured":"Lee B-S, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998. https:\/\/doi.org\/10.1210\/jcem.83.1.4503.","journal-title":"J Clin Endocrinol Metab"},{"key":"3429_CR53","doi-asserted-by":"crossref","unstructured":"Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-a at the translational level [Internet]. 2002. www.elsevier.com\/locate\/ejphar","DOI":"10.1016\/S0014-2999(02)01758-2"},{"key":"3429_CR54","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.transproceed2007.07.078","volume":"39","author":"A Dosanjh","year":"2007","unstructured":"Dosanjh A. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection. Transplant Proc. 2007;39:2153\u20136. https:\/\/doi.org\/10.1016\/j.transproceed2007.07.078.","journal-title":"Transplant Proc"},{"key":"3429_CR55","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02347-2021","author":"A Birnhuber","year":"2022","unstructured":"Birnhuber A, Jandl K, Biasin V, Flie\u00dfer E, Valzano F, Marsh LM, et al. Pirfenidone exacerbates Th2-driven vasculopathy in a mouse model of systemic sclerosis-associated interstitial lung disease. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.02347-2021.","journal-title":"Eur Respir J"},{"key":"3429_CR56","doi-asserted-by":"publisher","unstructured":"Bowler PG. Wound pathophysiology, infection and therapeutic options. Ann. Med. 2002. p. 419\u201327. https:\/\/doi.org\/10.1080\/078538902321012360","DOI":"10.1080\/078538902321012360"},{"key":"3429_CR57","doi-asserted-by":"publisher","unstructured":"Frykberg RG, Banks J. Challenges in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). Mary Ann Liebert Inc; 2015;4:560\u201382. https:\/\/doi.org\/10.1089\/wound.2015.0635","DOI":"10.1089\/wound.2015.0635"},{"key":"3429_CR58","doi-asserted-by":"publisher","unstructured":"Mecott GA, Gonz\u00e1lez-Cant\u00fa I, Dorsey-Trevi\u00f1o EG, Matta-Yee-Chig D, Saucedo-C\u00e1rdenas O, Montes De Oca-Luna R, et al. Efficacy and Safety of Pirfenidone in Patients with Second-Degree Burns: A Proof-of-Concept Randomized Controlled Trial. Adv. Skin Wound Care. Lippincott Williams and Wilkins; 2020. https:\/\/doi.org\/10.1097\/01.ASW.0000655484.95155.f7","DOI":"10.1097\/01.ASW.0000655484.95155.f7"},{"key":"3429_CR59","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.burns.2018.07.007","volume":"44","author":"G\u00c1 Mecott-Rivera","year":"2018","unstructured":"Mecott-Rivera G\u00c1, Aguilar-Baqueiro JA, Bracho S, Miranda-Maldonado I, Franco-M\u00e1rquez R, Castro-Govea Y, et al. Pirfenidone increases the epithelialization rate of skin graft donor sites. Burns. 2018;44:2051\u20138. https:\/\/doi.org\/10.1016\/j.burns.2018.07.007.","journal-title":"Burns"},{"key":"3429_CR60","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.11579","author":"DA Lopez-de la Mora","year":"2015","unstructured":"Lopez-de la Mora DA, Sanchez-Roque C, Montoya-Buelna M, Sanchez-Enriquez S, Lucano-Landeros S, Macias-Barragan J, et al. Role and new insights of pirfenidone in fibrotic diseases. Int J Med Sci. 2015. https:\/\/doi.org\/10.7150\/ijms.11579.","journal-title":"Int J Med Sci"},{"key":"3429_CR61","doi-asserted-by":"publisher","unstructured":"Wells AR, Leung KP. Pirfenidone attenuates the profibrotic contractile phenotype of differentiated human dermal myofibroblasts. Biochem Biophys Res Commun. Elsevier B.V.; 2020;521:646\u201351. https:\/\/doi.org\/10.1016\/j.bbrc.2019.10.177","DOI":"10.1016\/j.bbrc.2019.10.177"},{"key":"3429_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/SAP.0b013e31821b6d08","volume":"68","author":"J Armendariz-Borunda","year":"2012","unstructured":"Armendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, Gonzalez-Garc\u00eda I, Martinez-Fong D, Miranda RA, et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg. 2012;68:22\u20138. https:\/\/doi.org\/10.1097\/SAP.0b013e31821b6d08.","journal-title":"Ann Plast Surg"},{"key":"3429_CR63","doi-asserted-by":"publisher","unstructured":"Liu X, Yang Y, Guo X, Liu L, Wu K, Yu M. The Antiangiogenesis Effect of Pirfenidone in Wound Healing in Vitro. Journal of Ocular Pharmacology and Therapeutics. Mary Ann Liebert Inc.; 2017;33:693\u2013703. https:\/\/doi.org\/10.1089\/jop.2017.0007","DOI":"10.1089\/jop.2017.0007"},{"key":"3429_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1335","author":"A Torre","year":"2024","unstructured":"Torre A, Mart\u00ednez-S\u00e1nchez FD, Narvaez-Ch\u00e1vez SM, Herrera-Islas MA, Aguilar-Salinas CA, C\u00f3rdova-Gallardo J, et al. Pirfenidone use in fibrotic diseases: what do we know so far? Immunity Inflamm Dis. 2024. https:\/\/doi.org\/10.1002\/iid3.1335.","journal-title":"Immunity Inflamm Dis"},{"key":"3429_CR65","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Aceituno E, Reolid A, Rodr\u00edguez-Jim\u00e9nez P, Chicharro P, de Argila D. Photobiological study in pirfenidone-induced photosensitivity. Photodermatol. Photoimmunol. Photomed. Blackwell Publishing Ltd; 2020. p. 481\u20133. https:\/\/doi.org\/10.1111\/phpp.12582","DOI":"10.1111\/phpp.12582"},{"key":"3429_CR66","doi-asserted-by":"publisher","unstructured":"Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cellular and Molecular Life Sciences. 2014. p. 549\u201374. https:\/\/doi.org\/10.1007\/s00018-013-1349-6","DOI":"10.1007\/s00018-013-1349-6"},{"key":"3429_CR67","doi-asserted-by":"publisher","unstructured":"Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction\u2014from repair and remodeling to regeneration. Cell Tissue Res. Springer Verlag; 2016. p. 563\u201381. https:\/\/doi.org\/10.1007\/s00441-016-2431-9","DOI":"10.1007\/s00441-016-2431-9"},{"key":"3429_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.678530","author":"F Graziani","year":"2021","unstructured":"Graziani F, Lillo R, Crea F. Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2021.678530.","journal-title":"Front Cardiovasc Med"},{"key":"3429_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu204","author":"M Senni","year":"2014","unstructured":"Senni M, Paulus WJ, Gavazzi A, Fraser AG, D\u00edez J, Solomon SD, et al. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014. https:\/\/doi.org\/10.1093\/eurheartj\/ehu204.","journal-title":"Eur Heart J"},{"key":"3429_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028134","author":"Q Shi","year":"2011","unstructured":"Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, et al. In vitro effects of pirfenidone on cardiac fibroblasts: Proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS ONE. 2011. https:\/\/doi.org\/10.1371\/journal.pone.0028134.","journal-title":"PLoS ONE"},{"key":"3429_CR71","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med Nature Research. 2021;27:1477\u201382. https:\/\/doi.org\/10.1038\/s41591-021-01452-0.","journal-title":"Nat Med Nature Research"},{"key":"3429_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104694","author":"A Aimo","year":"2020","unstructured":"Aimo A, Cerbai E, Bartolucci G, Adamo L, Barison A, Lo Surdo G, et al. Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence. Pharmacol Res. 2020. https:\/\/doi.org\/10.1016\/j.phrs.2020.104694.","journal-title":"Pharmacol Res"},{"key":"3429_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000351179","volume":"126","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation. Cardiology. 2013;126:1\u201311. https:\/\/doi.org\/10.1159\/000351179.","journal-title":"Cardiology"},{"key":"3429_CR74","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10175-w","author":"A Aimo","year":"2022","unstructured":"Aimo A, Spitaleri G, Panichella G, Lup\u00f3n J, Emdin M, Bayes-Genis A. Pirfenidone as a novel cardiac protective treatment. Heart Fail Rev. 2022. https:\/\/doi.org\/10.1007\/s10741-021-10175-w.","journal-title":"Heart Fail Rev"},{"key":"3429_CR75","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s40267-017-0459-x","volume":"34","author":"KA Lyseng-Williamson","year":"2018","unstructured":"Lyseng-Williamson KA. Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use. Drugs Ther Perspect. 2018;34:8\u201315. https:\/\/doi.org\/10.1007\/s40267-017-0459-x.","journal-title":"Drugs Ther Perspect"},{"key":"3429_CR76","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s12325-017-0594-8","volume":"34","author":"L Pan","year":"2017","unstructured":"Pan L, Belloni P, Ding HT, Wang J, Rubino CM, Putnam WS. A pharmacokinetic bioequivalence study comparing pirfenidone tablet and capsule dosage forms in healthy adult volunteers. Adv Ther. 2017;34:2071\u201382. https:\/\/doi.org\/10.1007\/s12325-017-0594-8.","journal-title":"Adv Ther"},{"key":"3429_CR77","doi-asserted-by":"publisher","unstructured":"Kang J, Lee KH, Lee JH, Jeong YY, Choi SM, Kim HC, et al. Safety, effectiveness, and usefulness of higher-dose tablets of generic pirfenidone in patients with IPF: a nationwide observational study in South Korea. Front Pharmacol. Frontiers Media SA; 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1451447","DOI":"10.3389\/fphar.2024.1451447"},{"key":"3429_CR78","doi-asserted-by":"publisher","unstructured":"Co\u015fkun F, \u00c7illi A, Hanta I, Sevin\u00e7 C, \u00d6demi\u015f A, Ursava\u015f A. Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting. Turk J Med Sci. Turkiye Klinikleri; 2021;51:3082\u20138. https:\/\/doi.org\/10.3906\/sag-2102-262","DOI":"10.3906\/sag-2102-262"},{"key":"3429_CR79","doi-asserted-by":"crossref","unstructured":"Cottin V, Gu\u00e9guen S, Nunes H, Jouneau S, Crestani B, Bonniaud P, et al. Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort. 2022; https:\/\/doi.org\/10.1007\/s12325-021-01961-x\u00ef.","DOI":"10.1007\/s12325-021-01961-x"},{"key":"3429_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0510-4","author":"M Rodr\u00edguez-Castellanos","year":"2014","unstructured":"Rodr\u00edguez-Castellanos M, Tlacuilo-Parra A, S\u00e1nchez-Enr\u00edquez S, V\u00e9lez-G\u00f3mez E, Guevara-Guti\u00e9rrez E. Pirfenidone gel in patients with localized scleroderma: A phase II study. Arthritis Res Ther. 2014. https:\/\/doi.org\/10.1186\/s13075-014-0510-4.","journal-title":"Arthritis Res Ther"},{"key":"3429_CR81","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.2147\/DDDT.S84046","volume":"9","author":"H Meng","year":"2015","unstructured":"Meng H, Xu Y. Pirfenidone-loaded liposomes for lung targeting: Preparation and in vitro\/in vivo evaluation. Drug Des Devel Ther. 2015;9:3369\u201376. https:\/\/doi.org\/10.2147\/DDDT.S84046.","journal-title":"Drug Des Devel Ther"},{"key":"3429_CR82","doi-asserted-by":"publisher","unstructured":"Han M, Song Y, Liu S, Lu X, Su L, Liu M, et al. Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis. Front Pharmacol. Frontiers Media S.A.; 2022;13. https:\/\/doi.org\/10.3389\/fphar.2022.882678","DOI":"10.3389\/fphar.2022.882678"},{"key":"3429_CR83","doi-asserted-by":"publisher","unstructured":"Wang X, Wan W, Lu J, Liu P. Inhalable FN-binding liposomes or liposome-exosome hybrid bionic vesicles encapsulated microparticles for enhanced pulmonary fibrosis therapy. Int J Pharm. Elsevier B.V.; 2024;656. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124096","DOI":"10.1016\/j.ijpharm.2024.124096"},{"key":"3429_CR84","doi-asserted-by":"publisher","unstructured":"Lee WT, Lee H, Kim J, Jung Y, Choi E, Jeong JH, et al. Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis. Bioact Mater. KeAi Communications Co.; 2024;33:262\u201378. https:\/\/doi.org\/10.1016\/j.bioactmat.2023.11.005","DOI":"10.1016\/j.bioactmat.2023.11.005"},{"key":"3429_CR85","doi-asserted-by":"publisher","unstructured":"Chettupalli AK, Kakkerla A, Jadi RK, Uppu P, Ghazwani M, Hani U, et al. Design, development, and preclinical evaluation of pirfenidone-loaded nanostructured lipid carriers for pulmonary delivery. Sci Rep. Nature Research; 2025;15. https:\/\/doi.org\/10.1038\/s41598-025-90910-7","DOI":"10.1038\/s41598-025-90910-7"},{"key":"3429_CR86","doi-asserted-by":"publisher","unstructured":"Kim CG, Jang M, Oh C, Jeon OH, Choi BH, Kim K, et al. Pulmonary surfactant-based pirfenidone-loaded nanovesicles for inhalation therapy of idiopathic pulmonary fibrosis. Journal of Controlled Release. Elsevier B.V.; 2025;385. https:\/\/doi.org\/10.1016\/j.jconrel.2025.114005","DOI":"10.1016\/j.jconrel.2025.114005"},{"key":"3429_CR87","doi-asserted-by":"publisher","unstructured":"Dudhat K, Patel H. Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis. Futur J Pharm Sci. Springer Science and Business Media LLC; 2022;8. https:\/\/doi.org\/10.1186\/s43094-022-00419-3","DOI":"10.1186\/s43094-022-00419-3"},{"key":"3429_CR88","doi-asserted-by":"publisher","unstructured":"Maslanka Figueroa S, Fleischmann D, Beck S, Goepferich A. Thermodynamic, Spatial and Methodological Considerations for the Manufacturing of Therapeutic Polymer Nanoparticles. Pharm Res. Springer; 2020;37. https:\/\/doi.org\/10.1007\/s11095-020-2783-4","DOI":"10.1007\/s11095-020-2783-4"},{"key":"3429_CR89","doi-asserted-by":"publisher","unstructured":"Soni SR, Bhunia BK, Kumari N, Dan S, Mukherjee S, Mandal BB, et al. Therapeutically Effective Controlled Release Formulation of Pirfenidone from Nontoxic Biocompatible Carboxymethyl Pullulan-Poly(vinyl alcohol) Interpenetrating Polymer Networks. ACS Omega. Am Chem Soc. 2018;3:11993\u20132009. https:\/\/doi.org\/10.1021\/acsomega.8b00803","DOI":"10.1021\/acsomega.8b00803"},{"key":"3429_CR90","doi-asserted-by":"publisher","unstructured":"Bao S, Zou Y, Firempong CK, Feng Y, Yu Y, Wang Y, et al. Preparation and evaluation of sustained release pirfenidone-loaded microsphere dry powder inhalation for treatment of idiopathic pulmonary fibrosis. European Journal of Pharmaceutical Sciences. Elsevier B.V.; 2023;188. https:\/\/doi.org\/10.1016\/j.ejps.2023.106509","DOI":"10.1016\/j.ejps.2023.106509"},{"key":"3429_CR91","doi-asserted-by":"publisher","unstructured":"Shi J, Li T, Miao H, Miao H. Preparation and Evaluation of Pirfenidone Dry Powder by Spray Drying Technology. BIO Web Conf. EDP Sciences; 2023. https:\/\/doi.org\/10.1051\/bioconf\/20235902014","DOI":"10.1051\/bioconf\/20235902014"},{"key":"3429_CR92","doi-asserted-by":"publisher","unstructured":"Seto Y, Suzuki G, Kato M, Sato H, Onoue S. Novel inhalable powder formulation of pirfenidone with sustained release properties to improve pulmonary deposition. J Drug Deliv Sci Technol. Editions de Sante; 2024;94. https:\/\/doi.org\/10.1016\/j.jddst.2024.105487","DOI":"10.1016\/j.jddst.2024.105487"},{"key":"3429_CR93","doi-asserted-by":"publisher","unstructured":"Ullah A, Wang K, Wu P, Oupicky D, Sun M. CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGF\u0392-induced HSC-T6 cells activation. Int J Nanomedicine. Dove Medical Press Ltd.; 2019;14:2927\u201344. https:\/\/doi.org\/10.2147\/IJN.S171280","DOI":"10.2147\/IJN.S171280"},{"key":"3429_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103819","author":"K Togami","year":"2025","unstructured":"Togami K, Kanehira Y, Nakamura Y, Ishii H, Abe R, Yamamoto A, et al. Pirfenidone encapsulated in succinylated gelatin-coated liposomes exhibits sustained antifibrotic effects in vitro models of renal, pulmonary, and hepatic fibrosis. J Pharm Sci. 2025. https:\/\/doi.org\/10.1016\/j.xphs.2025.103819.","journal-title":"J Pharm Sci"},{"key":"3429_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122539","author":"MM AbouSamra","year":"2023","unstructured":"AbouSamra MM, Elgohary R, Mansy SS. Innovated pirfenidone loaded lecithin nanocapsules for targeting liver fibrosis: formulation, characterization and in vivo study. Int J Pharm. 2023. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122539.","journal-title":"Int J Pharm"},{"key":"3429_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020316","author":"CD Diaz-Palomera","year":"2022","unstructured":"Diaz-Palomera CD, Vidal-Paredes IA, Navarro-Partida J, Cid-Hernandez M, Rosales-Rivera LC, De la Rosa-Bibiano R, et al. Topical pirfenidone-loaded liposomes ophthalmic formulation reduces haze development after corneal alkali burn in mice. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14020316.","journal-title":"Pharmaceutics"},{"key":"3429_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070528","author":"S Chowdhury","year":"2013","unstructured":"Chowdhury S, Guha R, Trivedi R, Kompella UB, Konar A, Hazra S. Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0070528.","journal-title":"PLoS ONE"},{"key":"3429_CR98","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-020-01798-7","author":"EP Chung","year":"2020","unstructured":"Chung EP, Wells AR, Kiamco MM, Leung KP. Dual asymmetric centrifugation efficiently produces a poloxamer-based nanoemulsion gel for topical delivery of pirfenidone. AAPS PharmSciTech. 2020. https:\/\/doi.org\/10.1208\/s12249-020-01798-7.","journal-title":"AAPS PharmSciTech"},{"key":"3429_CR99","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/08982104.2015.1060611","volume":"26","author":"A Jose","year":"2016","unstructured":"Jose A, Mandapalli PK, Venuganti VVK. Liposomal hydrogel formulation for transdermal delivery of pirfenidone. J Liposome Res. 2016;26:139\u201347. https:\/\/doi.org\/10.3109\/08982104.2015.1060611.","journal-title":"J Liposome Res"},{"key":"3429_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071842","author":"EP Chung","year":"2023","unstructured":"Chung EP, Nguyen JQ, Tellkamp-Schehr T, Goebel K, Ollek A, Krein C, et al. A soft skin adhesive (SSA) patch for extended release of pirfenidone in burn wounds. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071842.","journal-title":"Pharmaceutics"},{"key":"3429_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27061830","author":"J He","year":"2022","unstructured":"He J, Meng X, Meng C, Zhao J, Chen Y, Zhang Z, et al. Layer-by-layer pirfenidone\/cerium oxide nanocapsule dressing promotes wound repair and prevents scar formation. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27061830.","journal-title":"Molecules"},{"key":"3429_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030206","author":"V Parvathaneni","year":"2020","unstructured":"Parvathaneni V, Kulkarni NS, Shukla SK, Farrales PT, Kunda NK, Muth A, et al. Systematic development and optimization of inhalable pirfenidone liposomes for non-small cell lung cancer treatment. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12030206.","journal-title":"Pharmaceutics"},{"key":"3429_CR103","doi-asserted-by":"publisher","unstructured":"Mpekris F, Papaphilippou PC, Panagi M, Voutouri C, Michael C, Charalambous A, et al. Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models. ACS Nano. Am Chem Soc. 2023;17:24654\u201367. https:\/\/doi.org\/10.1021\/acsnano.3c03305","DOI":"10.1021\/acsnano.3c03305"},{"key":"3429_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106501","author":"S Teworte","year":"2023","unstructured":"Teworte S, Aleandri S, Weber JR, Carone M, Luciani P. Mucoadhesive 3D printed vaginal ovules to treat endometriosis and fibrotic uterine diseases. Eur J Pharm Sci. 2023. https:\/\/doi.org\/10.1016\/j.ejps.2023.106501.","journal-title":"Eur J Pharm Sci"},{"key":"3429_CR105","doi-asserted-by":"publisher","unstructured":"Fayzullin A, Churbanov S, Ignatieva N, Zakharkina O, Tokarev M, Mudryak D, et al. Local delivery of pirfenidone by pla implants modifies foreign body reaction and prevents fibrosis. Biomed. MDPI AG; 2021;9. https:\/\/doi.org\/10.3390\/biomedicines9080853","DOI":"10.3390\/biomedicines9080853"},{"key":"3429_CR106","doi-asserted-by":"publisher","unstructured":"Cao X, Tao S, Wang W, Wu S, Hong Y, Wang X, et al. Ternary inulin hydrogel with long-term intestinal retention for simultaneously reversing IBD and its fibrotic complication. Nat Commun. Nature Research; 2024;15. https:\/\/doi.org\/10.1038\/s41467-024-52722-7","DOI":"10.1038\/s41467-024-52722-7"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03429-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:09:00Z","timestamp":1780502940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03429-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":106,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["3429"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03429-z","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The manuscript has been read and approved by all the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}